Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial
Abstract
The role of cholinergic abnormalities in autism was recently evidenced and there is a growing interest in cholinergic modulation, emerging for targeting autistic symptoms. Galantamine is an acetylcholinesterase inhibitor and an allosteric potentiator of nicotinic receptors. This study aimed to evaluate the possible effects of galantamine as an augmentative therapy to risperidone, in autistic children. In this randomized, double-blind, placebo-controlled, parallel-group study, 40 outpatients aged 4–12 years whom had a diagnosis of autism (DSM IV-TR) and a score of 12 or higher on the Aberrant Behavior Checklist-Community (ABC-C) Irritability subscale were equally randomized to receive either galantamine (up to 24 mg/day) or placebo, in addition to risperidone (up to 2 mg/day), for 10 weeks. We rated participants by ABC-C and a side effects checklist, at baseline and at weeks 5 and 10. By the study endpoint, the galantamine-treated patients showed significantly greater improvement in the Irritability (P = 0.017) and Lethargy/Social Withdrawal (P = 0.005) subscales than the placebo group. The difference between the two groups in the frequency of side effects was not significant. In conclusion, galantamine augmentation was shown to be a relatively effective and safe augmentative strategy for alleviating some of the autism-related symptoms.
Get full access to this article
View all access and purchase options for this article.
References
Abreu-Villaca Y, Filgueiras CC, Manhaes AC (2011) Developmental aspects of the cholinergic system. Behav Brain Res 221: 367–378.
Ago Y, Koda K, Takuma K, et al. (2011) Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 116: 6–17.
Akhondzadeh S, Fallah J, Mohammadi MR, et al. (2010) Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 34: 32–36.
Aman MG, Singh NN, Stewart AW, et al. (1985) The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89: 485–491.
American Psychiatric Association (2000) Diagnostic Criteria from Dsm-Iv-Tr. Washington, DC: American Psychiatric Association.
Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. (2013) Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. Psychopharmacology 225: 51–59.
Bauman ML, Kemper TL (2005) Neuroanatomic observations of the brain in autism: A review and future directions. Int J Dev Neurosci 23: 183–187.
Belluardo N, Mudo G, Blum M, et al. (2000) Neurotrophic effects of central nicotinic receptor activation. J Neural Transm 60: 227–245.
Bentley P, Vuilleumier P, Thiel CM, et al. (2003) Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. Neuroimage 20: 58–70.
Blaylock RL, Strunecka A (2009) Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem 16: 157–170.
Bruel-Jungerman E, Lucassen PJ, Francis F (2011) Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res 221: 379–388.
Chilian B, Abdollahpour H, Bierhals T, et al. (2013) Dysfunction of Shank2 and Chrna7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci. Clin Genet 8: e1002521.
Clementi F, Fornasari D, Gotti C (2000) Neuronal nicotinic receptors, important new players in brain function. Eur J Pharmacol 393: 3–10.
Craig D, Birks J (2006) Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev: CD004746.
Dajas-Bailador FA, Heimala K, Wonnacott S (2003) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol 64: 1217–1226.
De Souza FM, Busquet N, Blatner M, et al. (2011) Galantamine improves olfactory learning in the Ts65dn mouse model of Down syndrome. Sci Rep 1: e00137.
Deutsch SI, Urbano MR, Neumann SA, et al. (2010) Cholinergic abnormalities in autism: Is there a rationale for selective nicotinic agonist interventions? Clin Neuropharmacol 33: 114–120.
Friedman SD, Shaw DW, Artru AA, et al. (2003) Regional brain chemical alterations in young children with autism spectrum disorder. Neurology 60: 100–107.
Ghaemi SN, Gilmer WS, Dunn RT, et al. (2009) A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol 29: 291–295.
Ghaleiha A, Asadabadi M, Mohammadi MR, et al. (2013) Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 16: 783–789.
Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. (2012) A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev 43: 674–682.
Hertzman M (2003) Galantamine in the treatment of adult autism: A report of three clinical cases. Int J Psychiatry Med 33: 395–398.
Kumar B, Prakash A, Sewal RK, et al. (2012) Drug therapy in autism: A present and future perspective. Pharmacol Rep 64: 1291–1304.
Lam KS, Aman MG, Arnold LE (2006) Neurochemical correlates of autistic disorder: A review of the iterature. Res Dev Disabil 27: 254–289.
Lee M, Martin-Ruiz C, Graham A, et al. (2002) Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125: 1483–1495.
Litvinenko IV, Odinak MM, Mogil’naya VI, et al. (2008) Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 38: 937–945.
Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview - Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659–685.
Loy C, Schneider L (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev: CD001747.
Madaan V, Kinnan S, Daughton J, et al. (2006) Innovations and recent trends in the treatment of ADHD. Expert Rev Neurother 6: 1375–1385.
Maelicke A, Samochocki M, Jostock R (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 49: 279–288.
Martin-Ruiz CM, Lee M, Perry RH, et al. (2004) Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res 123: 81–90.
Mudo G, Belluardo N, Fuxe K (2007) Nicotinic receptor agonists as neuroprotective/ neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 114: 135–147.
Nelson KB, Grether JK, Croen LA, et al. (2001) Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49: 597–606.
Nicolson R, Craven-Thuss B, Smith J (2006a) A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 16: 621–629.
Nicolson R, Devito TJ, Vidal CN, et al. (2006b) Detection and mapping of hippocampal abnormalities in autism. Psychiatry Res 148: 11–21.
Niederhofer H, Staffen W, Mair A (2002) Galantamine may be effective in treating autistic disorder. Brit Med J 325: 1422.
Noda Y, Mouri A, Ando Y, et al. (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: Involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-Erk1/2 systems. Int J Neuropsychopharmacol 13: 1343–1354.
Ochoa EL, Clark E (2006) Galantamine may improve attention and speech in schizophrenia. Hum Psychopharmacol 21: 127–128.
Perry EK, Lee ML, Martin-Ruiz CM, et al. (2001) Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 158: 1058–1066.
Petersen AK, Ahmad A, Shafiq M, et al. (2013) Deletion 1q43 encompassing only Chrm3 in a patient with autistic disorder. Eur J Med Genet 56: 118–122.
Ray MA, Graham AJ, Lee M, et al. (2005) Neuronal nicotinic acetylcholine receptor subunits in autism: An immunohistochemical investigation in the thalamus. Neurobiol Dis 19: 366–377.
Rezaei V, Mohammadi MR, Ghanizadeh A, et al. (2010) Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 34: 1269–1272.
Rossignol DA (2009) Novel and emerging treatments for autism spectrum disorders: A systematic review. Ann Clin Psychiatry 21: 213–236.
Rubenstein JL, Merzenich MM (2003) Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2: 255–267.
Santos MD, Alkondon M, Pereira EF, et al. (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61: 1222–1234.
Schilstrom B, Ivanov VB, Wiker C, et al. (2007) Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacol 32: 43–53.
Schubert MH, Young KA, Hicks PB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60: 530–533.
Sharp BM, Yatsula M, Fu Y (2004) Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 309: 1116–1123.
Sokol DK, Dunn DW, Edwards-Brown M, et al. (2002) Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. J Child Neurol 17: 245–249.
Wang D, Noda Y, Zhou Y, et al. (2007) Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacol 52: 1179–1187.
Wiker C, Schilstrom B, Sandback C, et al. (2008) Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. Int J Neuropsychopharmacol 11: 845–850.
Wilens TE, Biederman J, Wong J, et al. (2000) Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. J Child Adolesc Psychopharmacol 10: 217–222.
Woolf NJ (1991) Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 37: 475–524.
Yasui DH, Scoles HA, Horike S, et al. (2011) 15q11.2–13.3 Chromatin analysis reveals epigenetic regulation of Chrna7 with deficiencies in Rett and autism brain. Hum Mol Genet 20: 4311–4323.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: October 15, 2013
Issue published: July 2014
Keywords
History
Published online: October 15, 2013
Issue published: July 2014
PubMed: 24132248
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in Journal of Psychopharmacology.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 527
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Web of Science: 50 view articles Opens in new tab
Crossref: 54
- Acetylcholinesterase inhibitors for autistic spectrum disorders
- Maternal Inflammation with Elevated Kynurenine Metabolites Is Related ...
- Systematic Review and Meta-analysis: Pharmacological and Nonpharmacolo...
- Catecholaminergic and cholinergic neuromodulation in autism spectrum d...
- Disease associations—Alzheimer’s disease, schizophrenia, Parkinson’s d...
- Galantamine beyond Alzheimer’s disease—a fact or artefact?
- Exploring the vagus nerve and the inflammatory reflex for therapeutic ...
- Anti-Anxiety Medications and Novel Treatments for Autism
- Autism Spectrum Disorder
- Targeted therapy with galantamine in a pediatric patient with 15q13.3 ...
- Impact of antipsychotics in children and adolescents with autism spect...
- Dysregulation of Neuronal Nicotinic Acetylcholine Receptor–Cholesterol...
- Treating disorders across the lifespan by modulating cholinergic signa...
- From Research to Practice: Toward the Examination of Combined Interven...
- Curcumin Potentiates α7 Nicotinic Acetylcholine Receptors and Alleviat...
- The evolving obesity challenge: targeting the vagus nerve and the infl...
- In silico Gene Set and Pathway Enrichment Analyses Highlight Involveme...
- Neurochemical Mechanisms of Pathogenesis and Pharmacological Correctio...
- The Pathogenesis and Complications Associated with Autism Spectrum Dis...
- Sulforaphane as an adjunctive treatment for irritability in children w...
- Drugs to Treat Dementia
- Role of Neuroinflammation in Autism Spectrum Disorder and the Emergenc...
- Resveratrol as adjunctive therapy in treatment of irritability in chil...
- The Neurochemistry of Autism
- An Evolving Therapeutic Rationale for Targeting the α7 Nicotinic Acety...
- Review of Clinical Studies Targeting Inflammatory Pathways for Individ...
- Risperidone Combination Therapy With Propentofylline for Treatment of ...
- Galanthum nivalis Extract is Neurologically Active and Improves Anxiet...
- Systematic review and guide to management of core and psychiatric symp...
- Autism throughout genetics: Perusal of the implication of ion channels
- Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and s...
- l -Carnosine As an Adjunctive Therapy to Risperidone in ...
- Galantamine alleviates inflammation and insulin resistance in patients...
- Galantamine
- New Assessments and Treatments in ASD
- Minocycline as Adjunctive Treatment to Risperidone in Children with Au...
- Postsynaptic nicotinic acetylcholine receptors facilitate excitation o...
- Modulatory effects of α7 nAChRs on the immune system and its relevance...
- Effects of augmentation agents in autistic disorder patients treated w...
- Update on psychopharmacology for autism spectrum disorders
- Autismus-Spektrum-Störungen
- Modulation of social deficits and repetitive behaviors in a mouse mode...
- The case of galantamine: repurposing and late blooming of a cholinergi...
- The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis an...
- A pilot double-blind placebo-controlled trial of pioglitazone as adjun...
- Predictors of placebo response in pharmacological and dietary suppleme...
- Neuronal effects of nicotine during auditory selective attention
- Nicotinic ACh receptors as therapeutic targets in CNS disorders
- Molecular Basis of Cholinergic Changes in Autism Spectrum Disorders an...
- Do We Know If They Work and If They Are Safe
- N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment...
- The Use of Medications Approved for Alzheimer’s Disease in Autism Sp...
- Potential Therapeutic Use of the Ketogenic Diet in Autism Spectrum Dis...
- An Update on Medication Management of Behavioral Disorders in Autism
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
